// App-Quantinova.ai

: CR4056, a first-in-class imidazoline-2 receptor ligand analgesic, in pain from knee osteoarthritis phenotypes: a randomized, placebo-controlled, double-blind, phase iia clinical trial

Researchers

Presenter

  • L. Rovati

Principal Investigators

  • N.J. Probert

  • T. Blicharski

  • N. Brambilla

  • C. Vitalini

  • F. Girolami

  • G. Giacovelli

  • M. D'Amato

Medical Centers

  • Rottapharm Biotech, Monza, Italy

  • MAC Clinical Research, Manchester, United Kingdom

  • Lubelskie Centrum Diagnostyczne, Świdnik, Poland

Locations

  • Italy

  • United Kingdom

  • Poland

Companies

  • N/A

Study Components

Therapeutic Area

  • Central Nervous System (CNS)

  • Musculoskeletal

  • Endocrine/metabolic Diseases (ME)

Disease

  • Knee osteoarthritis

  • Pain (neuropathic)

  • Osteoarthritis

  • Obesity

Biomarkers

  • Body mass index

  • Albumin/creatinine

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Multicenteric

  • Prospective

  • Controlled

  • Parallel Group

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved